Introduction Pazopanib is an dental vascular endothelial growth element receptor (VEGFR) tyrosine kinase inhibitor. reduced to 600 mg daily. In arm A of 9 evaluable individuals there was 1(11%) patient having a PSA response 3 (33%) with stable PSA and 5 (56%) with PSA progression; in arm B of 12 evaluable individuals: there were 2… Continue reading Introduction Pazopanib is an dental vascular endothelial growth element receptor (VEGFR)